Novo Nordisk’s stock price dropped significantly after the disappointing results of a clinical trial for its new obesity drug candidate, CagriSema. The trial showed less weight loss than expected, with a 25% target in mind. Despite this setback, Novo executive expressed optimism about the data, saying they were “encouraged” by the outcome.
However, the disappointing results wiped $125 billion from the company’s market value, highlighting the significant risks involved in developing new obesity treatments. CagriSema is considered a next-generation obesity drug candidate after Wegovy, which has been successful in helping patients with weight loss.
In response to the trial’s results, Novo plans to initiate a new trial in 2025 to further evaluate the effectiveness of CagriSema. As one analyst described it, this would be “the worst-case scenario” for investors, indicating that the company is taking proactive steps to address concerns about its obesity drug.
Despite the setback, Novo Nordisk remains committed to developing innovative treatments for obesity and other conditions, with a focus on improving patient outcomes.
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-next-gen-obesity-drug-cagrisema-achieves-lower-weight-loss-than-2024-12-20